**Abstract**

**Objective:** To identify pattern of proton magnetic resonance spectroscopy (1-H MRS) choline (Cho) and other metabolite changes in left amygdala and in left dorsolateral prefrontal cortex (DLPFC) after SSRI treatment as a single psychoactive medication in major depressive disorder (MDD).

**Methods:** In 17 responders and 11 non-responders Cho, N-acetyl aspartate (NAA), creatine (Cr), myo -Inositol (MI), lactate and glutamine and glutamate (Glx) peaks and their ratios were analysed by 1-H MRS on 3T scanner in left amygdala and in left DLPFC prior and after 2 months of SSRI treatment as monotherapy.

**Summary of results:** In responders, Cho/Cr in DLPFC significantly increased post-treatment (by 16.0%), whereas in amygdala it significantly decreased (by 6.1%). In non-responders there was no change in Cho/Cr in DLPFC, while Cho/Cr in amygdala moderately rose (by 2.5%). No significant changes in MI were observed in any group. Post-treatment improvement rate positively correlates with Cho/Cr increase in DLPFC (r=0.62) and inversely with Cho/Cr decrease in amygdala (r=-0.45). Cho/Cr changes between two analysed regions are highly correlated themselves (r=0.82). Metabolite changes were not dose dependent.

**Conclusion:** Our findings corroborate the evidence that Cho changes in 1H-MRS reflect metabolic effects of treatment. Results indicate the increased membranes turnover rate in responders in DLPFC (presumably due to phosphorylcholine-to-glycerophosphorylcholine mediated synthesis-to-breakdown overbalance) and decreased in amygdala, a finding congruent to amygdala-to-DLPFC functional connectivity shift observed in neuroimaging studies. High correlation in Cho/Cr changes between the two regions may likely be attributed to their involvement in the same functional circuitry. More profound and eventually class-specific 1-H MRS detectable effects appear to emerge as study medication was used as monotherapy, thus avoiding modulating effects of other psychoactive medications.
